Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. scores highest on Nitro (82) and lowest on Price (12). Its PosiPenta is 43.41 out of 100, around the middle of similar companies.
On the Penta Grid this week, Kymera Therapeutics, Inc. is Grid #424 of 837 in the Healthcare sector in United States, and Grid #2,553 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. | 43.41 | 12 | 17 | 82 | 61 | 45 |
| 10x Genomics, Inc. | 51.48 | 6 | 71 | 75 | 61 | 44 |
| Protagonist Therapeutics, Inc. | 51.93 | 11 | 45 | 81 | 79 | 44 |
| Twist Bioscience Corporation | 42.60 | 3 | 51 | 68 | 50 | 41 |
| Caris Life Sciences, Inc. | 62.42 | 39 | 47 | 93 | 57 | 77 |
| Hinge Health, Inc. | 62.78 | 22 | 56 | 94 | 82 | 60 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -32.24 |
| P/B ratio | 5.71 |
EEarnings
| Trailing EPS | ₹-307.82 |
| Forward EPS | ₹-482.80 |
NNitro
| Price | 9924.23 |
| 52-week high | 12317.68 |
| 52-week low | 5233.95 |
| Fall from 52-week high | 19.4% |
TTorque
| Return on equity (ROE) | -24.15% |
| Debt-to-equity | 0.05 |
AAnchor
| Beta (price swings) | 1.98 |
| Market cap | ₹81,634 Cr |
| Insider holding | 2.12% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Kymera Therapeutics, Inc.'s PosiPenta score?
Kymera Therapeutics, Inc.'s PosiPenta is 43.41 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Kymera Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Kymera Therapeutics, Inc. is Grid #424 of 837 in the Healthcare sector in United States, and Grid #2,553 of 4,000 in United States.
Which PosiPenta pillar is strongest for Kymera Therapeutics, Inc.?
Nitro (momentum), with a score of 82 out of 100: much better than most similar companies.
Which PosiPenta pillar is weakest for Kymera Therapeutics, Inc.?
Price (valuation), with a score of 12 out of 100: much weaker than most similar companies.
Has Kymera Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 1.86 points, from 41.55 to 43.41.
PositoAI is for research and education only and is not investment advice.